Strategies to Prevent Rapid Weight Regain Without Continuous Therapy If discontinuing semaglutide is necessary, evidence suggests that gradual dose reductionrather than abrupt cessationmay reduce rebound appetite severity and allow behavioral adaptations to solidify
These include CACNA1C, the NMDA receptor (NMDAR), and the G q -protein-coupled serotonin and ghrelin receptors [34]
Consequently, the definition of treatment success is also expanding beyond headline weight loss achieved, to include the full spectrum of patients therapeutic needs, for example: Effective and durable weight maintenance Managing co-morbidities along the cardio-metabolic-renal spectrum Preserving muscle mass Tolerability, safety Convenience, e.g., delivered via oral therapies and/or less-frequent dosing * Including diabetes, ASCVD, Afib, HTN, PAH, dyslipidaemia, heart failure, PAD, MI, stroke, cardiovascular disease, CKD Source: IQVIA LAAD
People who treat GLP-1 therapy as a window of opportunity, using the appetite suppression to build better habits rather than just eating less of the same foods, are the ones who maintain their results when the medication dose decreases or stops
Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a retrospective cohort study, which emulated a target trial using 2014 to 2024 electronic health record data to examine the association between GLP-1 RA use and major adverse cardiovascular and thromboembolic event risk among adults with obesity and AID
Enhanced Circulation
